deliverables

How inputs, assumptions, runs, and reports connect across the pipeline. The jumping-off point to everything else.

Where the demand envelope comes from and how it’s bounded.

Intervention onset timing: assumptions, evidence, downstream effect.

Interactive drill-down into remaining coverage headroom.

How long malaria products and analogues took from approval to first country launch, and a proposed optimistic, central and conservative N for each of the six novel classes in v104.

Decision sheet for aligning the PST portfolio input with IPM v103: two pipeline fixes, three structural differences, ten coverage conflicts and five further rows, each with a proposed stance.

Where each MIASMA input and each of the 32 assumption families should live, who owns it, when it moves, and the six decisions to settle with the PST.

What the YAML assumptions database and its editor are, how a value travels from file to OpenMalaria, how to run the sandbox on your own machine, and the roadmap to a version 1.0 both maintainers can operate before March 2027.

What the October Kids delivery did to the portfolio once the deck’s conservative gene-drive assumptions were baked in: product contributions, gene drive by country, burden trajectories, and the baseline that moved in six countries.

Reconciling the PST bubble/roll-up library with the Stage 3 product-contrast engine — same estimand verified, what’s adopted vs held, and the build plan for a native cost-effectiveness bubble with dominance handling.

Gene-drive dynamics from first principles, for a mixed technical/policy audience.

The Q4 plan: the 2027 contract, running OpenMalaria in house, extending the emulator for sensitivity and change decomposition, and an assumptions database built for the PST and other diseases, with every deferred item from the September audit folded into the workstream that owns it.

Why one childhood-EPI ceiling shouldn’t bound adult and endectocide products — and a menu of per-channel envelopes keyed to real coverage proxies.

Where each resistance series stands after the ACT switch to the OJ Watson study — source, method, and what to trust, product by product.

From a country-level urban guess to admin-level GHS-SMOD cities ∪ observed stephensi detections — the mismatch we found, the union rule, and what the data can’t yet tell us.

The implemented SoC cost update — Global Fund 2026 reference prices mix-weighted by real purchase volumes, delivery built from freight tables, SMC campaign budgets, and the ITN costing literature. Before/after comparison with decomposition graphics: commodities down, microscopy honestly up, SMC unchanged in total but rebuilt underneath.

The manual-acquisition list for the 2026 cost refresh — registration-gated, browser-only, PDF-locked and Internet-Archive-only sources, payoff-ranked, with the extraction traps that silently produce wrong numbers.

The manual-extraction list — registration-gated, browser-only, and PDF sources (IHME LBD, JRF, ESPEN, DHS) that take each prevention workstream from national to full subnational scope, payoff-ranked.

Does correcting the Stage-3 admin-population defect reconcile the model-vs-reference burden gap? It closes about half the deaths shortfall, widens the incidence gap, and leaves the CFR mismatch — a metric-definition difference.